抗血管生成：治疗发展的新前沿。 - Suppr

Suppr

超能文献

Antiangiogenesis: new frontiers in therapeutic development.

作者信息

LaMontagne Kenneth R

机构信息

Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey, USA.

出版信息

Angiogenesis. 2005;8(4):285-7. doi: 10.1007/s10456-005-9025-6. Epub 2006 Jan 7.

DOI:10.1007/s10456-005-9025-6

PMID:16400519

Abstract

摘要

相似文献

Antiangiogenesis: new frontiers in therapeutic development.

Angiogenesis. 2005;8(4):285-7. doi: 10.1007/s10456-005-9025-6. Epub 2006 Jan 7.

Novel agents target existing tumor vasculature.

Expert Rev Anticancer Ther. 2010 Mar;10(3):303.

Cancer angiogenesis: targeting the heel of Achilles.

J Drug Target. 2008 Jul;16(6):449-54. doi: 10.1080/10611860802088523.

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.

Molecular mechanisms and therapeutic development of angiogenesis inhibitors.

Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3.

Antiangiogenesis: the fifth cancer treatment modality?

Oncol Nurs Forum. 2003 Nov-Dec;30(6):934-44. doi: 10.1188/03.ONF.934-944.

Angiogenesis as a therapeutic target.

Nature. 2005 Dec 15;438(7070):967-74. doi: 10.1038/nature04483.

Recognition of tumor blood vessel normalization as a new antiangiogenic concept.

Nat Med. 2004 Apr;10(4):329; author reply 329-30. doi: 10.1038/nm0404-329a.

[Angiogenesis in cancer].

Medicina (B Aires). 2002;62(6):604-6.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23.

引用本文的文献

Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.

Int J Med Sci. 2013;10(2):110-8. doi: 10.7150/ijms.5123. Epub 2012 Dec 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Antiangiogenesis: new frontiers in therapeutic development.

Angiogenesis. 2005;8(4):285-7. doi: 10.1007/s10456-005-9025-6. Epub 2006 Jan 7.

Novel agents target existing tumor vasculature.

Expert Rev Anticancer Ther. 2010 Mar;10(3):303.

Cancer angiogenesis: targeting the heel of Achilles.

J Drug Target. 2008 Jul;16(6):449-54. doi: 10.1080/10611860802088523.

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.

Molecular mechanisms and therapeutic development of angiogenesis inhibitors.

Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3.

Antiangiogenesis: the fifth cancer treatment modality?

Oncol Nurs Forum. 2003 Nov-Dec;30(6):934-44. doi: 10.1188/03.ONF.934-944.

Angiogenesis as a therapeutic target.

Nature. 2005 Dec 15;438(7070):967-74. doi: 10.1038/nature04483.

Recognition of tumor blood vessel normalization as a new antiangiogenic concept.

Nat Med. 2004 Apr;10(4):329; author reply 329-30. doi: 10.1038/nm0404-329a.

[Angiogenesis in cancer].

Medicina (B Aires). 2002;62(6):604-6.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23.

引用本文的文献

Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.

Int J Med Sci. 2013;10(2):110-8. doi: 10.7150/ijms.5123. Epub 2012 Dec 28.